$ABBV | AbbVie Reports Positive Phase 3 Results for Lutikizumab AbbVie ($ABBV) announced positive topline results from its Phase 3 INTREPID trial, showing that lutikizumab improved symptoms of hidradenitis suppurativa (HS), a chronic inflammatory skin disease that causes painful lumps and abscesses. Key Highlights: 31.4% of patients receiving lutikizumab achieved a 75% reduction in skin lesions at Week 16, versus 23.4% with placebo. All 8 ranked secondary endpoints were met, including improvements in skin pain and disease flares. Disease flares occurred in 18.4% of treated patients versus 28.1% on placebo. AbbVie expects regulatory submissions in H2 2027, with additional trial data expected in 2027. The company also plans to explore lutikizumab alongside its experimental weight-loss drug ABBV-295, potentially targeting both inflammation and obesity-related disease burden. Why It Matters: This is a positive clinical milestone for $ABBV as it seeks to expand its immunology portfolio beyond existing drugs such as Skyrizi and Rinvoq. However, lutikizumab remains investigational and is not yet approved for this condition. Bottom Line: Positive Phase 3 results could create another growth opportunity for AbbVie, but regulatory approval and commercial success are still ahead. #ABBV #AbbVie #Biotech #ClinicalTrials #PharmaNews #HealthcareStocks